SCHEMBL145515

SCHEMBL145515

COC(=O)c1cc(Br)nc2c1[nH]c1cc(OCc3ccccc3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.49
GABRA1 P14867 2/20 0.48
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA3 P34903 2/20 0.48
GABRA2 P47869 2/20 0.48
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
SRD5A2 P31213 1/20 0.45
HSD17B10 Q99714 1/20 0.45
JAK2 O60674 1/20 0.45
MDH2 P40926 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHEK1 O14757 1/20 0.44
FLT3 P36888 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141099 0.87 JAK2 (0.58) MAOAGABRA1GABRG2GABRB3GABRA3
SCHEMBL145362 0.85 JAK2 (0.66) MAOAGABRA1GABRG2GABRB3GABRA3
SCHEMBL138263 0.84 JAK2 (0.57) ALDH1A1HPGDKDM4EHSD17B10JAK2
SCHEMBL142347 0.83 JAK2 (0.56) MAOAGABRA1GABRG2GABRB3GABRA3
SCHEMBL145786 0.81 JAK2 (0.43) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL147675 0.80 GABRP (0.45) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL143133 0.80 JAK2 (0.49) MAOAGABRA1GABRG2GABRB3GABRA3
SCHEMBL145169 0.78 NR4A2 (0.51) HPGDKDM4ECYP2C9JAK2CHEK1
SCHEMBL141121 0.78 JAK2 (0.42) ALDH1A1HPGDKDM4EHSD17B10JAK2
SCHEMBL140994 0.77 JAK2 (0.58) MAOAALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 MAOA 2218/4885GABRA1 2062/4885GABRG2 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.